Welcome to our dedicated page for Indivior Pharmaceuticals news (Ticker: INDV), a resource for investors and traders seeking the latest updates and insights on Indivior Pharmaceuticals stock.
Indivior Pharmaceuticals, Inc. reports developments in specialty pharmaceuticals for opioid use disorder, with recurring updates centered on SUBLOCADE, its monthly extended-release buprenorphine injection, and evidence supporting medications for opioid use disorder. Company news commonly covers financial results and guidance, commercial performance for SUBLOCADE, scientific and real-world evidence studies, and treatment-use discussions in settings such as correctional facilities.
Indivior updates also include capital-allocation actions, including share repurchase programs and convertible note financing, along with corporate presentations and investor communications tied to the Indivior Action Agenda. The company’s disclosures frame opioid use disorder as a chronic treatable brain disease and emphasize buprenorphine-based prescription treatments.
Indivior (Nasdaq: INDV) reported Q2 2026 total net revenue of $343 million, up 14% year-over-year, driven by record quarterly SUBLOCADE net revenue of $253 million, up 21%. U.S. SUBLOCADE revenue rose 22% to $238 million on 18% dispense unit growth and record 32,816 new patient starts.
Q2 2026 GAAP net income reached a record $122 million ($0.98 diluted EPS) and non-GAAP net income was $142 million ($1.15 diluted EPS). Adjusted EBITDA was a record $186 million, up 111% from Q2 2025, as GAAP operating expenses fell 25% to $134 million and non-GAAP operating expenses declined 33% to $112 million.
For full-year 2026, Indivior raised guidance, now expecting net revenue of $1,295–$1,365 million, total SUBLOCADE net revenue of $1,010–$1,050 million, and adjusted EBITDA of $700–$740 million, while maintaining non-GAAP operating expense guidance. The company repurchased approximately 4.7 million shares for $175 million in Q2 (8.6 million shares, $300 million year-to-date) and ended the quarter with $249 million in cash and investments. Indivior and Supernus also announced a definitive agreement for an all-stock merger of equals, expected to close in the fourth quarter of 2026.
Supernus Pharmaceuticals (Nasdaq: SUPN) and Indivior Pharmaceuticals (Nasdaq: INDV) agreed to a tax-free, all-stock merger of equals to form a diversified CNS biopharmaceutical company with pro forma net revenue of approximately $2.2 billion and pro forma adjusted EBITDA of $888 million, including $125 million in expected annual cost synergies.
Supernus stockholders will receive 1.5401 Indivior shares per share and Indivior stockholders will receive a one-time special cash dividend of $1.0 billion, funded by a committed $650 million term loan from Citibank N.A. and existing cash. Indivior holders will own about 56.5% of the combined company and Supernus holders about 43.5%. The merged entity will be named Supernus, Inc., listed on Nasdaq as SUPN, headquartered in Rockville, Maryland, led by Supernus CEO Jack Khattar as President and CEO and Indivior director Tony Kingsley as Board Chair. Closing is targeted for Q4 2026, subject to shareholder and regulatory approvals.
Indivior (Nasdaq: INDV) will release its second quarter 2026 financial results on Tuesday, August 4, 2026, at 7:00 a.m. U.S. EDT. At 8:00 a.m. U.S. EDT, CEO Joe Ciaffoni and the leadership team will host a live webcast presentation, accessible via the Investors section of www.indivior.com, with telephonic access by advance online registration and a replay available on the company’s website.
Indivior (Nasdaq: INDV) reported two real‑world evidence studies on monthly injectable buprenorphine (SUBLOCADE) in opioid use disorder.
Adherent patients were 3.5–8.1x less likely to return to opioid use, had 62% lower bacteremia incidence, and showed reduced inpatient, emergency, and outpatient healthcare utilization versus other MOUD or daily oral buprenorphine.
Indivior (Nasdaq: INDV) will participate in two June 2026 investor conferences. Management will attend the Jefferies Global Healthcare Conference in New York on June 3 and the Goldman Sachs 47th Annual Global Healthcare Conference in Miami on June 8, hosting 1x1 and group investor meetings.
Indivior (Nasdaq: INDV) announced a $175 million accelerated share repurchase (ASR) with Barclays under its existing $400 million buyback program on May 4, 2026. Indivior will pay $175 million upfront and expects an initial delivery of 3,717,473 shares, with final settlement tied to VWAP less a discount by end of June 2026. The company said the ASR is not expected to affect its previously issued financial guidance and that up to $100 million of the authorization remains available for future repurchases.
Indivior (Nasdaq: INDV) reported Q1 2026 results and raised full‑year guidance. Q1 total net revenue was $317 million (+19% YoY) and SUBLOCADE net revenue was $232 million (+32% YoY). Adjusted EBITDA was $164 million (+112% YoY). The company completed a $500 million convertible note offering and repurchased ~3.97 million shares for $125 million, leaving $275 million available under a $400 million repurchase program.
The company ceased internal development of INDV-6001 and will not advance INDV-2000 after Phase 2; guidance ranges for 2026 were raised for revenue and Adjusted EBITDA.
Indivior (NASDAQ: INDV) will present two posters at ASAM 2026 (April 23-26) reporting real-world and observational findings on monthly extended-release buprenorphine (BUP-XR, SUBLOCADE).
Findings link higher MOUD coverage and BUP-XR use to lower fatal and non-fatal overdose proportions, and associate 3-month remission with better craving, withdrawal, pain, quality of life, and employment outcomes.
Indivior (Nasdaq: INDV) reported results from a national survey of 180 U.S. correctional professionals showing strong support for long-acting injectable (LAI) buprenorphine to reduce medication-for-opioid-use-disorder (MOUD) diversion: 88% of jail and 87% of prison respondents endorsed its potential to help.
Respondents cited staffing, custody-health coordination, operational medication challenges, cost, and limited access as barriers to MOUD implementation and sustainable delivery during incarceration and reentry.
Indivior (Nasdaq: INDV) will report first quarter 2026 financial results on Thursday, April 30, 2026 at 7:00 a.m. U.S. EDT. A live webcast presentation with CEO Joe Ciaffoni and other leaders will follow at 8:00 a.m. U.S. EDT.
Investors can access the live webcast and materials on the company’s Investors webpage; a replay will be available after the event.